Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CureVac stock

CVAC
NL0015436031
A2P71U

Price

2.93
Today +/-
+0.10
Today %
+3.64 %

CureVac stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CureVac stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CureVac stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CureVac stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CureVac's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CureVac Stock Price History

DateCureVac Price
3/4/20252.93 undefined
3/3/20252.82 undefined
3/2/20252.94 undefined
2/27/20252.99 undefined
2/26/20252.94 undefined
2/25/20253.06 undefined
2/24/20253.01 undefined
2/23/20253.12 undefined
2/20/20253.15 undefined
2/19/20253.12 undefined
2/18/20253.16 undefined
2/17/20253.37 undefined
2/13/20253.48 undefined
2/12/20253.49 undefined
2/11/20253.53 undefined
2/10/20253.42 undefined
2/9/20253.60 undefined
2/6/20253.47 undefined
2/5/20253.59 undefined
2/4/20253.62 undefined

CureVac Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CureVac, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CureVac from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CureVac’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CureVac. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CureVac’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CureVac’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CureVac’s growth potential.

CureVac Revenue, EBIT and net profit per share

DateCureVac RevenueCureVac EBITCureVac Net Income
2030e298.71 M undefined0 undefined0 undefined
2029e258.09 M undefined108.59 M undefined-124.14 M undefined
2028e201.4 M undefined56.26 M undefined-121.83 M undefined
2027e216.63 M undefined77.49 M undefined187.57 M undefined
2026e109.33 M undefined-87.79 M undefined-64.07 M undefined
2025e65.73 M undefined-106.88 M undefined-115.56 M undefined
2024e452.95 M undefined194.61 M undefined170.86 M undefined
202353.76 M undefined-269.69 M undefined-260.17 M undefined
202267.4 M undefined-225 M undefined-249 M undefined
2021103 M undefined-478.7 M undefined-411.7 M undefined
202048.9 M undefined-109.8 M undefined-129.1 M undefined
201917.4 M undefined-99.5 M undefined-99.9 M undefined
201812.9 M undefined-72.8 M undefined-71.2 M undefined

CureVac Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e2030e
121748103675345265109216201258298
-41.67182.35114.58-34.95-20.90752.83-85.6267.6998.17-6.9428.3615.50
-33.33-58.8270.83-131.07-135.82-116.98-13.72-95.38-56.88-28.70-30.85-24.03-20.81
-4-1034-135-91-620000000
-71-99-129-411-249-260170-115-64187-121-1240
-39.4430.30218.60-39.424.42-165.38-167.65-44.35-392.19-164.712.48-
176.5176.5180.5187.1195220.480000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The CureVac Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CureVac is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201820192020202120222023
           
0.060.031.320.810.50.4
6.917.21.818.5917.08
1.91.52.22.72.65.93
36.214.556.22424.8
0.81.248.349.250.726.18
0.070.061.390.940.580.48
40.561.7100.6200.4241.7278.63
000000
0.7111.10.30
6.25.714.113.219.315.88
000012.512.46
5.25.15.73.52.72.9
52.673.5121.4218.2276.5309.87
0.130.131.511.160.860.79
           
0.70.721.722.523.426.88
000000
31.4-43.6689.6671.9511.5490.13
001000-100-67
000000
32.1-42.9711.4694.4534.8516.94
95.321.7127.773.548.03
12.312.15046.839.349.48
6.88.7172.7179.838.583.88
000000
0.123.23.555.01
28.228.1247.6357.8156.3186.39
077.15225.437.136.82
01.60000
65.466.6500.386.6133.948.1
65.4145.3552.311217184.92
93.6173.4799.9469.8327.3271.31
0.130.131.511.160.860.79
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CureVac provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CureVac's financial health and stability.

Assets

CureVac's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CureVac must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CureVac after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CureVac's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
-71-100-129-412-249
37101523
00-1-10
0-1460215-128
-103954-33576
00894
00000
-74-87522-733-286
-14-12-47-127-93
-428-45-127-93
1040200
00000
068-47-28-4
008673730
06881934563
000066
00000
-0.080.011.29-0.51-0.32
-88.8-99.2475-861-379.4
00000

CureVac stock margins

The CureVac margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CureVac. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CureVac.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CureVac's sales revenue. A higher gross margin percentage indicates that the CureVac retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CureVac's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CureVac's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CureVac's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CureVac. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CureVac's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CureVac Margin History

CureVac Gross marginCureVac Profit marginCureVac EBIT marginCureVac Profit margin
2030e-116.3 %0 %0 %
2029e-116.3 %42.07 %-48.1 %
2028e-116.3 %27.93 %-60.49 %
2027e-116.3 %35.77 %86.59 %
2026e-116.3 %-80.3 %-58.6 %
2025e-116.3 %-162.6 %-175.81 %
2024e-116.3 %42.97 %37.72 %
2023-116.3 %-501.67 %-483.96 %
2022-135.91 %-333.83 %-369.44 %
2021-131.26 %-464.76 %-399.71 %
202070.96 %-224.54 %-264.01 %
2019-60.92 %-571.84 %-574.14 %
2018-37.98 %-564.34 %-551.94 %

CureVac Stock Sales Revenue, EBIT, Earnings per Share

The CureVac earnings per share therefore indicates how much revenue CureVac has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CureVac earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CureVac's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CureVac’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CureVac's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CureVac Revenue, EBIT and net profit per share

DateCureVac Sales per ShareCureVac EBIT per shareCureVac Earnings per Share
2030e1.33 undefined0 undefined0 undefined
2029e1.15 undefined0 undefined-0.55 undefined
2028e0.9 undefined0 undefined-0.54 undefined
2027e0.97 undefined0 undefined0.84 undefined
2026e0.49 undefined0 undefined-0.29 undefined
2025e0.29 undefined0 undefined-0.52 undefined
2024e2.02 undefined0 undefined0.76 undefined
20230.24 undefined-1.22 undefined-1.18 undefined
20220.35 undefined-1.15 undefined-1.28 undefined
20210.55 undefined-2.56 undefined-2.2 undefined
20200.27 undefined-0.61 undefined-0.72 undefined
20190.1 undefined-0.56 undefined-0.57 undefined
20180.07 undefined-0.41 undefined-0.4 undefined

CureVac business model

CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac is one of the most popular companies on Eulerpool.com.

CureVac SWOT Analysis

Strengths

  • Strong research and development capabilities, enabling innovation and development of potential breakthrough mRNA-based therapies and vaccines.
  • Broad and diverse pipeline of product candidates, providing potential for growth in different therapeutic areas.
  • Strategic partnerships and collaborations with leading pharmaceutical companies, enhancing the company's research, development, and commercialization capabilities.

Weaknesses

  • Dependence on the success of mRNA platform technology, which is a relatively new and evolving field with potential regulatory and technical challenges.
  • Limited commercial experience and lack of a marketed product, posing risks in terms of revenue generation and market acceptance.
  • Reliance on a few key product candidates, making the company vulnerable to potential failures or delays in clinical trials.

Opportunities

  • Increasing demand for mRNA-based therapies and vaccines, driven by advancements in personalized medicine and the need for innovative treatment options.
  • Expansion into new therapeutic areas and global markets, leveraging partnerships, collaborations, and potentially licensing agreements.
  • Potential for strategic alliances with governments, organizations, or research institutions to accelerate development and distribution of mRNA-based vaccines during global health crises.

Threats

  • Intense competition in the mRNA-based therapeutics field, with established and emerging biopharmaceutical companies vying for market share.
  • Uncertainties related to clinical trial outcomes, regulatory approvals, and intellectual property rights, which could impact the company's ability to bring products to market.
  • Economic and regulatory factors, such as pricing pressures, reimbursement policies, and changing healthcare systems, that may impact product commercialization and profitability.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CureVac Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CureVac historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CureVac shares outstanding

The number of shares was CureVac in 2024 — This indicates how many shares 220.481 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CureVac earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CureVac's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CureVac’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CureVac's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for CureVac.

CureVac latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.57 1.5  (161.42 %)2024 Q3
6/30/2024-0.27 -0.32  (-18.39 %)2024 Q2
3/31/2024-0.23 -0.31  (-33.28 %)2024 Q1
12/31/2023-0.19 -0.39  (-106.68 %)2023 Q4
9/30/2023-0.23 -0.22  (5.42 %)2023 Q3
6/30/2023-0.24 -0.3  (-22.55 %)2023 Q2
3/31/2023-0.35 -0.27  (22.15 %)2023 Q1
12/31/2022-0.31 -0.6  (-91.27 %)2022 Q4
9/30/2022-0.27 -0.25  (8.09 %)2022 Q3
6/30/2022-0.26 -0.31  (-18.41 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the CureVac stock

Eulerpool World ESG Rating (EESG©)

27/ 100

🌱 Environment

27

👫 Social

41

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CureVac shareholders

%
Name
Stocks
Change
Date
31.28366 % DH Capital GmbH & Co. KG70,181,76003/15/2024
13.31525 % KfW29,871,44103/15/2024
7.39589 % Glaxo Group, Ltd.16,591,93703/15/2024
4.50311 % DH-LT-Investments GmbH10,102,28603/15/2024
1.51764 % Zweite DH Verwaltungs GmbH3,404,67203/15/2024
0.73417 % Millennium Management LLC1,647,037-771,13612/31/2024
0.69933 % Bill & Melinda Gates Foundation1,568,866-28,7719/30/2024
0.26999 % BlackRock Institutional Trust Company, N.A.605,690-215,49712/31/2024
0.22703 % Aperio Group, LLC509,32999,12312/31/2024
0.22478 % UBS Financial Services, Inc.504,268444,59412/31/2024
1
2
3
4
5
...
10

CureVac Executives and Management Board

Mr. Pierre Kemula

(49)
CureVac Chief Financial Officer, Member of the Management Board
Compensation 548,918

Dr. Igor Splawski

(55)
CureVac Chief Scientific Officer, Member of the Management Board
Compensation 483,640

Dr. Antony Blanc

(55)
CureVac Chief Business Officer, Chief Commercial Officer, Member of the Management Board
Compensation 467,213

Dr. Malte Greune

(58)
CureVac Chief Operating Officer, Member of the Management Board
Compensation 426,900

Mr. Baron Stephenne

(72)
CureVac Independent Chairman of Supervisory Board (since 2015)
Compensation 123,750
1
2
3

Most common questions regarding CureVac

What values and corporate philosophy does CureVac represent?

CureVac NV represents a commitment to transforming the lives of patients through groundbreaking mRNA technology. With a strong corporate philosophy centered on innovation, quality, and collaboration, the company strives to develop and deliver mRNA-based therapeutics and vaccines to address a wide range of diseases, including cancer and infectious diseases. CureVac NV's values are built upon scientific excellence, patient-centricity, and sustainability. By harnessing the power of mRNA, the company aims to revolutionize healthcare and improve global health outcomes. Through continuous research and strategic partnerships, CureVac NV demonstrates its dedication to advancing the field of mRNA-based medicine and making a positive impact on society.

In which countries and regions is CureVac primarily present?

CureVac NV is primarily present in various countries and regions. The company's presence spans across Europe, including Germany, Switzerland, and Austria, where its headquarters and research facilities are located. CureVac NV also has a strong presence in the United States, with operations in Cambridge, Massachusetts. The company's global expansion efforts have led to its presence in other regions, such as Latin America, Africa, and Asia, as it collaborates with partners and conducts clinical trials worldwide. With its widespread presence and international collaborations, CureVac NV is dedicated to advancing mRNA-based technologies and developing innovative solutions on a global scale.

What significant milestones has the company CureVac achieved?

CureVac NV, a renowned biopharmaceutical company, has attained several significant milestones in its journey. Notably, CureVac NV successfully completed its initial public offering (IPO) in August 2020, raising substantial capital for its research and development activities. Moreover, the company has made noteworthy advancements in the development of mRNA-based vaccines and therapeutics, showcasing promising results in preclinical and clinical trials. CureVac NV has also established strategic partnerships with various leading pharmaceutical companies, such as Bayer, GSK, and the Bill & Melinda Gates Foundation, further strengthening its research and commercialization capabilities. With its pioneering approach and collaborative efforts, CureVac NV continues to revolutionize the field of mRNA-based healthcare solutions.

What is the history and background of the company CureVac?

CureVac NV is a biopharmaceutical company specializing in developing messenger RNA (mRNA) therapeutics and vaccines. Founded in 2000, CureVac has a rich history of groundbreaking mRNA research. The company is headquartered in Tübingen, Germany, and has expanded its presence globally, including the establishment of CureVac Inc. in the United States. CureVac has pioneered the use of mRNA as a platform for various therapeutic applications, including cancer treatments, infectious diseases, and rare diseases. As a leading player in the field, CureVac has collaborated with numerous strategic partners and received significant funding for its innovative mRNA technology, demonstrating its promising potential in revolutionizing the medical industry.

Who are the main competitors of CureVac in the market?

Some of the main competitors of CureVac NV in the market are Moderna Inc., BioNTech SE, and Pfizer Inc. These companies also specialize in the development of mRNA-based therapeutics and vaccines. However, CureVac NV differentiates itself through its proprietary RNAoptimizer platform, which enables efficient, scalable, and cost-effective mRNA production. With its innovative technology and a strong pipeline of candidates, CureVac NV aims to create a significant presence in the market.

In which industries is CureVac primarily active?

CureVac NV is primarily active in the biotechnology industry.

What is the business model of CureVac?

The business model of CureVac NV focuses on the development of transformative messenger RNA (mRNA) therapeutics and vaccines. By leveraging its proprietary mRNA platform, CureVac aims to address various diseases and medical conditions across multiple therapeutic areas, including infectious diseases, oncology, and rare diseases. Their mRNA technology allows for the production of vaccine candidates and therapeutic proteins, which can be customized to target specific diseases. This innovative approach offers potential advantages such as rapid development, scalability, and adaptability. As a leading biopharmaceutical company, CureVac NV seeks to revolutionize the field of medicine through the use of mRNA to provide innovative treatment options for patients worldwide.

What is the P/E ratio of CureVac 2025?

The CureVac P/E ratio is -5.59.

What is the P/S ratio of CureVac 2025?

The CureVac P/S ratio is 9.82.

What is the Quality Investing of CureVac?

The Quality Investing for CureVac is 3/10.

What is the revenue of CureVac 2025?

The expected CureVac revenue is 65.73 M EUR.

How high is the profit of CureVac 2025?

The expected CureVac profit is -115.56 M EUR.

What is the business model of CureVac

CureVac NV is a biotechnology company based in Tübingen, specializing in the development of mRNA-based therapies and vaccines. The company's business model is based on basic research and the development of innovative technologies for the production of mRNA-based products. One of CureVac's key areas is the development of mRNA vaccines. The company uses its platform technology to produce mRNA molecules that stimulate the body's immune system and induce a protective immune response. CureVac has already developed several vaccine candidates for diseases such as COVID-19 and cancer, which are currently in clinical development. Another focus of the company is the development of mRNA therapies. This involves using mRNA technology to produce therapeutic proteins or antibodies in the body to treat diseases. CureVac's therapy areas include cancer, rare diseases, and infectious diseases. To develop and manufacture these technologies, CureVac has its own research and development as well as production facilities. The company utilizes mRNA technology to produce clinical and commercial quantities of mRNA products. CureVac follows a highly automated and standardized production process to ensure high quality and large quantities of products. Collaboration with industry and scientific partners is also an important part of CureVac's business model. The company has formed partnerships with various pharmaceutical companies to jointly work on the development of mRNA-based therapies and vaccines. Additionally, CureVac works closely with universities and research institutions to advance basic research on mRNA technology. To expand the applications of its technology, CureVac continuously invests in researching new mRNA platforms and developing new technologies to improve the delivery of mRNA products in the body. This will allow for effective treatment of a wider range of diseases. In summary, CureVac's business model is based on the development and application of mRNA technology for the production of therapeutic proteins, antibodies, and vaccines. The company engages in both research and development activities and operates its own production facility, while collaborating with industry and scientific partners. With the use of its platform technology and continuous innovation, CureVac aims to effectively treat a wider range of diseases.

What is the CureVac dividend?

CureVac pays a dividend of 0 EUR distributed over payouts per year.

How often does CureVac pay dividends?

The dividend cannot currently be calculated for CureVac or the company does not pay out a dividend.

What is the CureVac ISIN?

The ISIN of CureVac is NL0015436031.

What is the CureVac WKN?

The WKN of CureVac is A2P71U.

What is the CureVac ticker?

The ticker of CureVac is CVAC.

How much dividend does CureVac pay?

Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.

What is the dividend yield of CureVac?

The current dividend yield of CureVac is .

When does CureVac pay dividends?

CureVac pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CureVac?

CureVac paid dividends every year for the past 0 years.

What is the dividend of CureVac?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is CureVac located?

CureVac is assigned to the 'Health' sector.

Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CureVac from 3/6/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did CureVac pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of CureVac in the year 2024?

In the year 2024, CureVac distributed 0 EUR as dividends.

In which currency does CureVac pay out the dividend?

The dividends of CureVac are distributed in EUR.

All fundamentals about CureVac

Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.